Cancer immunotherapy targeting survivin: commentary re: V. Pisarev et al., full-length dominant-negative survivin for cancer immunotherapy. Clin. Cancer Res., 9:6523-6533, 2003.
Reed
John C
JC
The Burnham Institute, La Jolla, California 92037, USA. reedoffice@burnham.org
Wilson
Darcy B
DB
D000818:Animals; D017951:Antigen Presentation; D005799:Genes, Dominant; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D051034:Inhibitor of Apoptosis Proteins; D051379:Mice; D008869:Microtubule-Associated Proteins / Q000737:chemistry* / Q000235:genetics; D008954:Models, Biological; D009363:Neoplasm Proteins; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D000077022:Survivin
C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D000077022:Survivin